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Objective: To determine the utility of ankle-brachial index (ABI) in screening for unrecognized peripheral arterial disease
(PAD). Although PAD is a consistent predictor of cardiovascular morbidity and mortality, it is often under-diagnosed
and under-treated.
Methods: In this prospective, observational, real-life, epidemiologic study (ELLIPSE) the prevalence of PAD (ABI< 0.9)
was calculated in 2146 asymptomatic patients >55 years of age who were at high cardiovascular risk and who were
hospitalized in departments of cardiology, diabetology, geriatrics, internal medicine, or neurology in metropolitan
France. Univariate and multivariate analyses were performed to identify PAD risk factors. The discriminatory power of
the model was evaluated by calculating the area under the curve (AUC) of the receiver operating characteristic curve.
Results: The ABI was<0.9 in 41.1% of patients. In the multivariate analysis, absence of>1 pulse (odds ratio [OR], 2.18;
95% confidence interval [CI], 1.81 to 2.63; P < .0001), arterial bruit (OR, 1.92; 95%CI, 1.34 to 2.75; P < .0004),
previous non-Q-wave myocardial infarction (OR, 1.50; 95%CI, 1.08 to 2.08; P  .02), regular smoking (OR, 1.49;
95%CI, 1.22 to 1.80; P < .0001), age >81 years (OR, 1.45; 95%CI, 1.15 to 1.82; P  .001), creatinine clearance <60
mL/min (OR, 1.33; 95%CI, 1.08 to 1.63; P .008), and treated hypertension (OR, 1.28; 95%CI, 1.03 to 1.59; P .03)
were significantly associated with PAD. Although risk increased with the number of variables, the model, based on clinical
symptoms and on medical history parameters, was not discriminatory (AUC  0.66). On average, physicians took 15
minutes to perform the ABI test.
Conclusions: The high prevalence of asymptomatic PAD in this patient population suggests that ABI should systemat-
ically be performed in high-risk hospitalized patients to ensure that appropriate secondary prevention programs are
initiated. (J Vasc Surg 2009;50:572-80.)The importance of prompt diagnosis and treatment of
lower limb peripheral arterial disease (PAD), a chronic
obstructive disease of the arteries, has been repeatedly
underscored. Peripheral arterial disease affects approxi-
mately 30% of community-based patients at cardiovascular
risk and is associated with significant increases in cardiovas-
cular morbidity and mortality.1-4 Nearly half of all PAD
patients die of cerebro-cardiovascular complications;4 and
as early as 1-year after diagnosis, cardiovascular mortality
rates are 3.7-fold higher in patients with PAD than in those
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572without.5 One-year data from the REduction of Athero-
thrombosis for Continued Health (REACH) registry con-
firm these findings, where patients with PAD experience
the highest rates of cardiovascular death and major cardio-
vascular event amongst patients with established arterial
disease.6,7 These high morbi-mortality rates can be de-
creased with statins, antiplatelet, and angiotensin convert-
ing enzyme treatments, all of which have been shown to
improve prognosis significantly.8-10 In the CAPRIE trial,
for example, treatment with clopidogrel significantly re-
duced vascular death, nonfatal myocardial infarction, and
nonfatal stroke in patients with PAD.11 Similarly, in the
HOPE study, treatment with ramipril reduced the risk of
cardiovascular outcomes in patients with PAD.12
Although the condition is well described and the over-
all public health implications are well understood, PAD is
still under-diagnosed and under-treated throughout Eu-
rope and the United States.3,4,13-15 Under-diagnosis is
largely attributable to the fact that up to half of PAD
patients can be asymptomatic;16,17 and intermittent clau-
dication, the main symptom, is only present in a fraction of
patients.3 The ankle-brachial index (ABI), by contrast, is a
symptom-independent tool that has been available for
many years and that can be used reliably to evaluate PAD.18It can easily be calculated from ankle and brachial blood
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a quick and cost-effective method of establishing or
refuting lower extremity PAD, this tool is underused
both in the community and in hospitals.19,20 Barriers to
the more widespread use of ABI were identified in the
PARTNERS (PAD Awareness, Risk, and Treatment:
New Resources for Survival) program to include time
constraints, lack of reimbursement and staff availability.21
Lastly, the extent of under-treatment was illustrated in the
French general practice study, ATTEST, which showed
that patients with PAD received treatment with angiotensin
converting enzyme inhibitors, statins, and antiplatelet
agents significantly less often than patients with coronary
artery disease or a history of stroke (13% vs 30%).13
To increase early diagnosis in France, we designed a
hospital-based study that would determine the prevalence
of PAD in high-risk hospitalized patients not previously
diagnosed with PAD, evaluate risk factors, and analyze
barriers to ABI use.
MATERIALS AND METHODS
Study design
This observational, epidemiologic, multicenter, pro-
spective, cross-sectional study, named ELLIPSE, was per-
formed under real-life clinical practice conditions in cardi-
ology, diabetology, geriatrics, internal medicine, and
neurology departments in hospitals throughout metropol-
itan France between April and November 2007. ELLIPSE
is derived from the French study name “Depistage de
L’arteriopathie obliterante des membres inferieurs à l’aide
de la mesure de L’Index de Pression Systolique en milieu
hospitalier”. Physicians were asked to collect data pertain-
ing to patient characteristics, cardiovascular risk factors,
cardiovascular history, and current hospitalization during
patient-physician interviews. Physicians assessed patients
for the presence of PAD, which was indicated by the
existence of pain or intermittent claudication, arterial bruit,
hair loss, ungual dystrophy, atrophic skin, wounds/ulcers,
and neuropathy and the absence of peripheral pulses. For
calculation of ABI, blood pressure measurements were
performed on both sides (brachial systolic and diastolic
blood pressure [DBP] and dorsalis pedis and posterior
tibial arterial systolic blood pressure [SBP]) by Doppler
([D811-B ultrasonic Doppler flow detector; Parks Medical
Electronics Inc, Las Vegas, Nev] or D-D EOS mano-poire
sphygmomanometer [Dessillons-Dutrillaux, Maison Al-
fort, France]). All physicians were trained to perform these
measurements. After enrollment of his/her last patient,
each physician was asked to evaluate the ABI measurement
procedure by filling out a questionnaire containing ques-
tions about ease of performance, time required, and per-
ceived relevance. The study protocol was reviewed and
approved by local Institutional Review Boards and the
National Council of the Order of Physicians, and was
performed in accordance with French law and with the
principles described in the Helsinki declaration.Patient population
Patients were included if they were 55 years of age
and were hospitalized in the department of cardiology,
diabetology, geriatrics, internal medicine, or neurology.
Patients had to have one of the following: (1) documented
coronary disease (angina [stable or unstable], or myocardial
infarction [Q-wave or non-Q-wave]), (2) documented ce-
rebrovascular disease (ischemic cerebrovascular accident or
transient ischemic attack), (3) documented polyvascular
disease (defined as both coronary and cerebrovascular dis-
ease), or (4) at least one cardiovascular risk factor (hyper-
cholesterolemia treated with an antilipidemic, hypertension
treated with an antihypertensive, diabetes type I or II
treated with a hypoglycemic or by diet, or smoking of at
least one cigarette a day either currently or at any time in
the past). Patients were excluded if previously diagnosed
with PAD or if they were hemodynamically unstable. To
ensure that the selected patients formed a representative
cohort, each participating physician included the first 10
patients who met study criteria and who were hospitalized
in their department after start of study.
Statistical analysis
The primary analysis population included all patients
meeting study criteria who had a difference in brachial
pressure (SBP-DBP) 20 mm Hg and for whom all four
measures of ankle arterial pressure were performed (SBP of
the dorsalis pedis and posterior tibial arteries on both
sides). The ABI was calculated according to the following
formula:22
ABI
min(SBPankle)
max(SBPbrachial)
This method of calculating ABI has been reported to
have greater sensitivity than using the higher of the two
ankle pressures, with only a modest decrease in specific-
ity.22 For purposes of comparison, we also calculated ABI
using the following formula that was derived from the
standard method of calculating ABI:23
ABI
max(SBPankle)
max(SBPbrachial)
Univariate and multivariate analyses. Univariate
analyses (Student t tests,  tests, or Wilcoxon signed ranked
tests) were performed to identify risk factors for PAD
(defined as an ABI 0.90). Predefined chosen variables
were age (55-62 years, 63-72, 73-80, 81 years and 81
years vs 81 years), gender, type of patient (coronary,
cerebrovascular, polyvascular, carrying at least one cardio-
vascular risk factor), documented coronary disease (overall,
stable angina, unstable angina, myocardial infarction [non-
Q-wave or without ST segment elevation], myocardial
infarction [Q-wave or with ST segment elevation]), docu-
mented cerebrovascular disease (overall, ischemic cerebro-
vascular accident or transient ischemic attack), presence of
cardiovascular risk factors (at least one of treated hypercho-
lesterolemia, treated hypertension, treated diabetes, regular
Revascularization, carotid n (%) 23 (1.1%)
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aneurysm of the abdominal aorta, renal artery angioplasty
or bypass, coronary artery angioplasty or bypass, angina
[stable or unstable], myocardial infarction [Q-wave or non-
Q-wave], symptomatic cardiac insufficiency due to isch-
emia, ischemic cerebrovascular accident, transient ischemic
attack, carotid revascularization), moderate or severe renal
insufficiency (creatinine clearance 60 mL/min), absence
of at least one peripheral pulse, presence of arterial bruit,
hospital department (cardiology, diabetology, geriatrics,
internal medicine, neurology), and type of hospital (teach-
ing hospital, district hospitals, regional hospitals).
For multivariate analysis, a step by step logistic regres-
sion was performed using the variables that were significant
(10%) in the univariate analysis. Pairwise comparisons were
performed. If a correlation between two variables was
found (Spearman’s rank correlation coefficient 0.60),
only the first of the two variables was included in the final
model. To evaluate the discriminatory power of the model,
a receiver operating characteristic (ROC) curve was con-
structed and area under the curve (AUC) was calculated.
Discriminatory power was defined as acceptable if AUC
0.7.
Power calculation. To estimate the PAD frequency
with 2% precision, the enrollment goal was 2500 patients.
This calculation assumed a 5% rate of unusable question-
naires and use of two-sided tests with   0.05.
RESULTS
Between April and November 2007, 2444 patient
questionnaires were collected by 255 hospital physicians
throughout France. After exclusion of 298 patients, the
primary population included 2146 patients who were re-
cruited by 249 physicians. The most frequent reason for
patient exclusion was absence of an ankle SBP measure-
ment (n  254). Other reasons included age 55 years/
data not available (n  22), previously diagnosed PAD/
data not available (n  13), SBP-DBP 20 mm Hg/data
not available (n  13), and absence of cardiovascular risk
factors/data not available (n  8). Patients who were
excluded because of missing data were very similar to study
patients (data not shown).
Cohort characteristics
Mean age of patients was 72.4  10.4 years and 52%
Table I. Continued.
Total (n  2146)
Creatinine clearance, mL/
min (n  2007) mean (SD) 69.3 (32.3)
Creatinine clearance, 60
mL/min n (%) 848 (39.5%)
SD, Standard deviation; doc, documented.
aCoronary  cerebrovascular.
bIncludes polyvascular patients.Table I. Characteristics of the primary analysis population
Total (n  2146)
Age, years Mean (SD) 72.4 (10.4)
55-62 years n (%) 480 (22.4%)
63-72 years n (%) 579 (27.0%)
73-80 years n (%) 537 (25.0%)
81 years n (%) 550 (25.6%)
Gender, male n (%) 1115 (52.0%)
Body mass index, kg/m2
(n  2058) Mean (SD) 26.8 (5.5)
Type of hospital
Teaching n (%) 1034 (48.2%)
District n (%) 876 (40.8%)
Regional n (%) 236 (11.0%)
Hospital department
Cardiology n (%) 480 (22.4%)
Diabetology n (%) 476 (22.2%)
Geriatrics n (%) 299 (13.9%)
Internal medicine n (%) 486 (22.6%)
Neurology n (%) 405 (18.9%)
Type of patient
Coronary n (%) 571 (26.6%)
Cerebrovascular n (%) 425 (19.8%)
Polyvasculara n (%) 150 (7.0%)
At cardiovascular risk only n (%) 1000 (46.6%)
Coronary disease, doc
Overallb n (%) 721 (33.6%)
Angina, stable n (%) 300 (14.0%)
Angina, unstable n (%) 135 (6.3%)
Myocardial infarction,
non-Q-wave n (%) 172 (8.0%)
Myocardial infarction,
Q-wave n (%) 282 (13.1%)
Cerebrovascular disease, doc
Overallb n (%) 575 (26.8%)
Cerebrovascular accident,
ischemic n (%) 473 (22.0%)
Transient ischemic attack n (%) 148 (6.9%)
Cardiovascular risk factors
At least 1 n (%) 2067 (96.3%)
Hypercholesterolemia,
treated n (%) 967 (45.1%)
Hypertension, treated n (%) 1601 (74.6%)
Diabetes, treated n (%) 942 (43.9%)
Smoker, regular n (%) 787 (36.7%)
Antecedents
At least 1 n (%) 846 (39.4%)
Aneurysm of the
abdominal aorta n (%) 24 (1.1%)
Renal artery bypass or
angioplasty n (%) 10 (0.5%)
Angina, stable n (%) 268 (12.5%)
Angina, unstable n (%) 106 (4.9%)
Myocardial infarction,
non-Q-wave n (%) 112 (5.2%)
Myocardial infarction,
Q-wave n (%) 203 (9.5%)
Coronary artery bypass or
angioplasty n (%) 270 (12.6%)
Symptomatic cardiac
insufficiency, ischemic n (%) 169 (7.9%)
Cerebrovascular accident,
ischemic n (%) 270 (12.6%)
Transient ischemic attack,
doc n (%) 102 (4.8%)were male (Table I). On average, patients were slightly
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creatinine clearance was60mL/min in 39.5% of patients.
At least one cardiovascular risk factor was carried by 96.3%
of patients. The population was divided between coronary
patients (26.6%), cerebrovascular patients (19.8%), polyvas-
cular (both coronary and cerebrovascular) patients (7.0%),
and patients who carried at least one cardiovascular risk
factor but had neither coronary nor cerebrovascular disease
(46.6%). Of the 787 regular smokers, only 27.6% were
current regular smokers, and 85.9% of the former regular
smokers had stopped for at least 3 years prior to study
enrollment.
During PAD evaluation (Table II), only 20.5% of pa-
tients reported lower limb pain. Newly identified intermit-
tent claudication was reported by 4.4% of patients. One or
more pulses were absent in 763 patients (35.6%) overall. Of
the 763 patients who had at least one pulse absent, 45.3%
did not have PAD and 54.7% had PAD. Arterial bruit was
recorded in the lower limbs in 6.8% of patients. The pro-
portion of patients with a mean lowest ankle SBP of 300
mm Hg was broadly similar across hospital departments
(cardiology, 0.2% [1/480]; diabetology, 0.0% [0/476];
geriatric, 0.7% [2/299], internal medicine, 0.4% [2/486];
Table II. Evaluation of peripheral arterial disease
Total
(n  2146)
Pain in lower limb n (%) 439 (20.5%)
Claudication, intermittent n (%) 93 (4.4%)
Claudication, non-intermittent n (%) 255 (12.0%)
Pain, at rest n (%) 210 (9.9%)
Lower limb pulse
Normal n (%) 1187 (55.3%)
Abnormal n (%) 763 (35.6%)
Data missing n (%) 196 (9.1%)
Arterial bruit
Present n (%) 147 (6.8%)
Absent n (%) 1493 (69.6%)
Data missing n (%) 506 (23.6%)
SBP, brachial, highest, mm Hg Mean (SD) 138 (22)
Min-Max 80-250
SBP, ankle lowest, mm Hg Mean (SD) 126 (34)
Min-Max 15-300
Ankle-brachial index Mean (SD) 0.92 (0.23)
Min-Max 0.13-2.75
Ankle-brachial index 0.5 72 (3.4%)
0.5-0.7 238 (11.1%)
0.7-0.9 572 (26.7%)
0.9-1.1 956 (44.5%)
1.1-1.3 254 (11.8%)
1.3 54 (2.5%)
Ankle-brachial index 0.9c n (%) 882 (41.1%)
95% CI 39.0 to 43.2
Ankle-brachial index 0.9d n (%) 453 (21.1%)
95% CI 19.4 to 22.9
SD, Standard deviation; min, minimum; max, maximum; SBP, systolic bloo
aCoronary  cerebrovascular.
bWith cardiovascular risk factors but neither coronary nor cerebrovascular d
cCalculated using formula described in Methods section.22
dCalculated by the conventional method (see Methods23).neurology, 0.2% [1/405]).Mean ABI was 0.92  0.23, and was 0.9 in 41.1% of
patients.MeanABI decreasedwith age; in patients63 years,
ABI was 0.96  0.18 vs 0.86  0.25 in patients 81 years.
Further, approximately twice as many patients 81 years
(52%) had an ABI 0.9 compared with those 63 years of
age (27.9%).WhenABIwas stratified by patient type, ABIwas
0.9 in 44.1% of coronary patients (mean ABI 0.91 0.24),
41.9% of cerebrovascular patients (mean ABI 0.91  0.23),
48.7% of polyvascular patients (mean ABI 0.87 0.25), and
in 37.9% of patients with only cardiovascular risk factors
(mean ABI 0.94  0.22). When ABI was stratified by
hospital department, ABI was 0.9 in 39.8% of patients in
cardiology, 35.3% of those in diabetology, 50.2% of those
in geriatrics, 44.7% of those in internal medicine, and 38.5%
of those in neurology. Comparing patients with treated
diabetes vs patients without treated diabetes, the prevalence
of ABI values of 1.3 (3.0 vs 2.2%) was not markedly
different between these two groups.
Ankle-brachial Index determination led to a marked
change in the distribution of patient types (Fig 1). Almost
38% of the population initially assessed as only at risk, had
PAD (17.7% of the total population). Furthermore, the
percentage of polyvascular patients, which was initially 7%,
oronary
n  571)
Cerebrovascular
(n  425)
Polyvasculara
(n  150)
At riskb
(n  1000)
3 (18.0%) 65 (15.3%) 26 (17.3%) 245 (24.6%)
6 (4.6%) 15 (3.6%) 11 (7.6%) 41 (4.2%)
2 (10.9%) 36 (8.6%) 12 (8.2%) 145 (14.7%)
2 (7.4%) 33 (7.8%) 12 (8.2%) 123 (12.4%)
5 (58.7%) 238 (56.0%) 72 (48.0%) 542 (54.2%)
9 (34.9%) 160 (37.6%) 62 (41.3%) 342 (34.2%)
7 (6.5%) 27 (6.4%) 16 (10.7%) 116 (11.6%)
8 (6.7%) 25 (5.9%) 11 (7.3%) 73 (7.3%)
1 (75.5%) 305 (71.8%) 100 (66.7%) 657 (65.7%)
2 (17.9%) 95 (22.4%) 39 (26.0%) 270 (27.0%)
3 (22) 143 (22) 139 (22) 140 (21)
80-250 90-220 96-202 80-230
0 (34) 129 (33) 121 (38) 130 (33)
30-300 30-300 20-280 15-300
1 (0.24) 0.91 (0.23) 0.87 (0.25) 0.94 (0.22)
.20-2.50 0.19-2.31 0.17-2.00 0.13-2.75
8 (3.2%) 17 (4.0%) 11 (7.3%) 26 (2.6%)
6 (13.3%) 48 (11.3%) 29 (19.3%) 85 (8.5%)
8 (27.7%) 113 (26.6%) 33 (22.0%) 268 (26.8%)
0 (42.0%) 185 (43.5%) 58 (38.7%) 473 (47.3%)
8 (11.9%) 51 (12.0%) 15 (10.0%) 120 (12.0%)
1 (1.9%) 11 (2.6%) 4 (2.7%) 28 (2.8%)
2 (44.1%) 178 (41.9%) 73 (48.7%) 379 (37.9%)
.0 to 48.3 37.2 to 46.7 40.4 to 57.0 34.9 to 41.0
8 (22.4%) 109 (25.6%) 47 (31.3%) 169 (16.9%)
.1 to 26.1 21.6 to 30.1 24.0 to 39.4 14.6 to 19.4
sure.
.C
(
10
2
6
4
33
19
3
3
43
10
13
12
0.9
0
1
7
15
24
6
1
25
40
12
19
d pres
iseaseincreased to 27% after ABI measurement.
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In univariate analyses, the proportion of patients with
PAD varied significantly with hospital department and in-
creased significantly with age, coronary disease, treated
hypertension, regular smoking, and cardiovascular ante-
cedents and creatinine clearance (Table III). Furthermore,
the proportion of patients with PAD increased with ab-
sence of a peripheral pulse and presence of arterial bruit in
the lower limbs.
In multivariate analyses, risk was multiplied by 2.18
with the absence of one or more pulses in the lower limbs
(P .0001) and by 1.92 with the presence of arterial bruit
(P  .0004) (Fig 2). Other significant variables were pre-
vious non-Q-wave MI (OR, 1.5), regular smoking (OR,
1.49), age81 years (OR, 1.45), creatinine clearance60
mL/min (OR, 1.33), and treated hypertension (OR,
1.28).
The risk of PAD increased with the number of the
Fig 1. Distribution of patients before and after ankle-brachial
index calculation for peripheral arterial disease. A, At inclusion,
high risk, asymptomatic patients were divided into four groups:
patients with (1) documented coronary disease, (2) documented
cerebrovascular disease, (3) documented polyvascular disease
(both coronary and cerebrovascular disease), and (4) at least one
cardiovascular risk factor but no coronary or cerebrovascular dis-
ease. B, After ankle-brachial index calculation. *Coronary patients
with PAD and cerebrovascular patients with PAD were counted as
polyvascular patients. PAD, Peripheral arterial disease.variables (Fig 3). The AUC of the ROC curve was 0.66.Ankle-brachial index test assessment
On average, physicians took 15 minutes to perform the
ABI test. Most physicians (96.8%) considered that this time
requirement was acceptable or short and that the test was
relatively easy to perform. Although 36.9% of physicians
experienced problems performing the test, this was for the
most part attributable to insufficient time (given as the
reason by 58.9% of physicians who experienced problems).
Most physicians considered the test worthwhile for high-
risk patients (93.0%) and asymptomatic patients (83.8%).
DISCUSSION
Although the beginning stages of PAD are often
asymptomatic and early symptoms are often dismissed by
subjects as “just leg pain”, morbidity and mortality associ-
ated with this serious condition is significant and could be
reduced if patients were diagnosed early and appropriate
treatment was initiated promptly. In this study, named
ELLIPSE, we determined that 41% of undiagnosed, high-
risk, patients, over the age of 55 and hospitalized in met-
ropolitan France in the departments of cardiology, diabe-
tology, geriatrics, internal medicine, or neurology, had
PAD. This high prevalence rate suggests that systematic
calculation of the ABI in this high-risk population should
be considered to increase early diagnosis of PAD.
PAD is prevalent amongst hospitalized, high-risk
patients
This study, which is among the first performed in
France, expands our knowledge of the prevalence of PAD
in hospitalized patients. Previous studies, which found
lower PAD rates (30%), were performed in lower risk
patients such as patients hospitalized for nonvascular dis-
eases and cardiovascular outpatients followed by general
practitioners.
1, 24
In the Swiss Atherothrombosis Survey, the
occurrence of PAD was assessed in everyday Swiss practice
using ABI. The study revealed that 3.7% of patients had
symptomatic PAD and an additional 2.7% with undiag-
nosed PAD. ABI was considered a reliable identification
tool of atherothrombotic events by 93.9% of general prac-
titioners.25 These variations in prevalence rates most likely
reflect the fact that these studies were performed in very
different patient populations. Data presented here are con-
sistent with those recorded in a Spanish hospital-based
study in which 40% of patients admitted for acute coronary
syndrome had PAD26 and suggest that hospitalized, high-
risk patients over the age of 55 have a higher rate of
undiagnosed PAD than those in the general community or
those hospitalized for nonvascular diseases.
The choice of method for calculation of ABI could
explain part of the apparent heterogeneity in prevalence
rates. As there is no consensus on ABI calculation, methods
vary, thereby affecting estimates.27 According to current
guidelines of the American Heart Association and Inter-
Society Consensus for the Management of Peripheral Arte-
rial Disease (TASC II), the standard calculation for ABI is
defined as the ratio between the highest SBP of the two
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Peripheral arterial disease
(n  882)
No peripheral arterial disease
(n  1264) P
Age, years Mean (SD) 74.7 (10.1) 70.9 (10.3) .001a
55-62 years n (%) 134 (15.2%) 346 (27.4%) .001
63-72 years n (%) 213 (24.1%) 366 (29.0%) —
73-80 years n (%) 249 (28.2%) 288 (22.8%) —
81 years n (%) 286 (32.4%) 264 (20.9%) —
Gender, male n (%) 443 (50.2%) 672 (53.2%) .168
Type of hospital .703
Teaching n (%) 422 (47.8%) 612 (48.4%) —
District n (%) 357 (40.5%) 519 (41.1%) —
Regional n (%) 103 (11.7%) 133 (10.5%) —
Hospital department
Cardiology n (%) 191 (21.7%) 289 (22.9%) .001
Diabetology n (%) 168 (19.0%) 308 (24.4%) —
Geriatrics n (%) 150 (17.0%) 149 (11.8%) —
Internal medicine n (%) 217 (24.6%) 269 (21.3%) —
Neurology n (%) 156 (17.7%) 249 (19.7%) —
Type of patient .018
Coronary n (%) 252 (28.6%) 319 (25.2%) .086
Cerebrovascular n (%) 178 (20.2%) 247 (19.5%) .714
Polyvascularb n (%) 73 (8.3%) 77 (6.1%) .052
At cardiovascular risk only n (%) 379 (43.0%) 621 (49.1%) .005
Coronary disease, doc
Overall n (%) 325 (36.8%) 396 (31.3%) .008
Angina, stable n (%) 135 (15.3%) 165 (13.0%) —
Angina, unstable n (%) 65 (7.4%) 70 (5.5%) —
Myocardial infarction, non-Q-wave n (%) 87 (9.9%) 85 (6.7%) —
Myocardial infarction, Q-wave n (%) 129 (14.6%) 153 (12.1%) —
Cerebrovascular disease, doc
Overall n (%) 251 (28.5%) 324 (25.6%) .147
Cerebrovascular accident, ischemic n (%) 199 (22.6%) 274 (21.7%) —
Transient ischemic attack n (%) 72 (8.2%) 76 (6.0%) —
Cardiovascular risk factors
At least 1 n (%) 855 (96.9%) 1212 (95.9%) .198
Hypercholesterolemia, treated n (%) 385 (44.2%) 582 (46.5%) .299
Hypertension, treated n (%) 687 (78.4%) 914 (72.7%) .002
Diabetes, treated n (%) 393 (44.8%) 549 (43.9%) .689
Smoker, regular n (%) 351 (40.2%) 436 (34.7%) .010
Antecedents
At least 1 n (%) 383 (43.4%) 463 (36.6%) .002
Aneurysm of the abdominal aorta n (%) 13 (1.5%) 11 (0.9%) .197
Renal artery bypass or angioplasty n (%) 5 (0.6%) 5 (0.4%) .572
Angina, stable n (%) 125 (14.2%) 143 (11.4%) .049
Angina, unstable n (%) 51 (5.8%) 55 (4.4%) .139
Myocardial infarction, non-Q-wave n (%) 56 (6.4%) 56 (4.4%) .051
Myocardial infarction, Q-wave n (%) 101 (11.5%) 102 (8.1%) .009
Coronary artery bypass or angioplasty n (%) 124 (14.1%) 146 (11.6%) .086
Symptomatic cardiac insufficiency, ischemic n (%) 90 (10.3%) 79 (6.3%) .001
Cerebrovascular accident, ischemic n (%) 115 (13.1%) 155 (12.3%) .593
Transient ischemic attack, doc n (%) 48 (5.5%) 54 (4.3%) .217
Revascularization, carotid n (%) 11 (1.3%) 12 (1.0%) .516
Creatinine clearance, 60 mL/min n (%) 412 (46.7%) 436 (34.5%) .001
Lower limb pulse .001
Normal n (%) 394 (44.7%) 793 (62.7%) —
Abnormal n (%) 417 (47.3%) 346 (27.4%) —
Data missing n (%) 71 (8.0%) 125 (9.9%) —
Arterial bruit .001
Present n (%) 85 (9.6%) 62 (4.9%) —
Absent n (%) 618 (70.1%) 875 (69.2%) —
Data missing n (%) 179 (20.3%) 327 (25.9%) —
Ankle-brachial index Mean (SD) 0.73 (0.15) 1.05 (0.17) .001c
Min-Max 0.13-0.90 0.90-2.75
0.5 n (%) 72 (8.2%) 0 .001
0.5-0.7 n (%) 238 (27.0%) 0 —
0.7-0.9 n (%) 572 (64.9%) 0 —
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highest of the two SBPs of the upper limbs.19,23 Indeed,
when we applied this calculation method to our data,
PAD estimates were about 20% lower, as expected. How-
ever, the observed difference in terms of prevalence
between the two methods of calculation is similar to that
Table III. Continued.
0.9-1.1 n (%)
1.1-1.3 n (%)
1.3 n (%)
Ankle-brachial index 0.9 n (%)
SD, Standard deviation; doc, documented.
2 test used except for aStudent t test.
bCoronary  cerebrovascular.
cWilcoxon signed rank test.
Fig 2. Multivariate analysis. Risk of peripheral arterial disease
significantly increased with absence of 1 pulse, arterial bruit,
previous non-Q-wave MI, smoking, age 81 years, creatinine
clearance 60 mL/min, and treated hypertension. Odds ratios
and 95% CI are presented. CI, Confidence intervals; creat Cl,
creatinine clearance; MI, myocardial infarction; OR, odds ratio;
TIA, transient ischemic attack.
Fig 3. Receiver operating characteristic curve. Risk increased
with the number of risk factors for peripheral arterial disease. Area
under the curve was 0.66. Model was not considered discrimina-
tory. AUC, Area under the curve; FPR, false positive rate; TPR,
true positive rate.reported previously.27 Use of the standard calculation hashigh sensitivity and specificity, but in symptomatic individ-
uals,23 thus we propose that it may be better suited for use
in patients with confirmed PAD. The standard definition
has also been challenged by recent studies that suggest that
using the lowest ankle SBP measurement allows for a
stronger association with PAD in systematic duplex sono-
graphic evaluations22 as well as a better prediction of car-
diovascular prognosis.28 Thus, the use of the lowest ankle
SBP for the definition of ABI in our population, provid-
ing greater sensitivity with only a modest decrease in
specificity,22 seemed warranted in order to identify more
patients at risk. We therefore feel confident that the 41%
prevalence rate reported here gives us a good estimate of
the prevalence of asymptomatic PAD in hospitalized high-
risk patients in France.
ABI, but not our prediction model, is a useful
diagnostic tool for PAD
To help physicians identify patients more easily, we
built a clinical prediction model using variables that have
been described in the literature as risk factors for
PAD.1,3,16,24,29-32 The German getABI study, for exam-
ple, identified older age, diabetes, hypertension, lipid dis-
orders, coexisting atherothrombotic disease, and previous
cerebrovascular or cardiovascular events as risk factors.29 In
the United States NHANES study, black race, smoking,
diabetes, hypertension, hypercholesterolemia, and poor
kidney function were associated with PAD;32 and at least
one cardiovascular disease risk factor was identified in 95%
of patients.32 As expected, in this study, several of these
variables, including, age, smoking, hypertension, and renal
insufficiency, were significantly associated with PAD. Inter-
estingly, diabetes, which is often identified in risk analyses,
was not statistically significant here. A similar finding was
reported by Bendermacher and coworkers.16 In some pa-
tients with diabetes or renal insufficiency, vascular calcifica-
tion may result in the tibial vessels becoming poorly- or
noncompressible; this may lead to a false elevation of the
ankle pressure, and typically an ABI of 1.40.23 The dia-
betic patients involved in this study, however, had a lower
cardiovascular risk, fewer comorbid conditions, and conse-
quently were less likely to have a pathological ABI, possibly
explaining why diabetes did not emerge as an independent
risk factor. Despite the increase in risk with the number of
heral arterial disease
(n  882)
No peripheral arterial disease
(n  1264) P
0 956 (75.6%) —
0 254 (20.1%) —
0 54 (4.3%) —
882 (100.0%) 0 .001Peripvariables included in the analysis, the overall model was not
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warrant use in a clinical setting.
The ABI has been recognized by guidelines as a quick
and cost-effective method of establishing or refuting lower
extremity PAD. It has been described by more than 89% of
physicians in the PARTNERS program as a useful diagnos-
tic tool for both symptomatic and asymptomatic PAD.19,21
Despite these endorsements, ABI is still underused in clin-
ical settings.19,20 The PARTNERS program study revealed
that in the United States, time constraints (56%), lack of
staff availability (45%), and lack of reimbursement (45%)
were the biggest barriers to its systematic use.21 We find
that most physicians considered that the test was worth-
while for high-risk (93%) and asymptomatic patients (84%)
and that the time required to perform the test was accept-
able (97%). These data suggest that if hospitals made the
Doppler device more readily available, more physicians
would use it to evaluate PAD in high-risk cardiovascular
patients over the age of 55.
One of the major findings from this study is the change
in patient risk level after ABI calculation. Almost 38% of the
population initially assessed as only at risk, had PAD (17.7%
of the total population). Furthermore, the percentage of
polyvascular patients, which was approximately 7% initially,
rose to more than 25% after ABI measurement (the defini-
tion of polyvascular included coronary patients with asymp-
tomatic PAD and cerebrovascular patients with asymptom-
atic PAD). These data have significant implications in terms
of treatment strategies as we know from the REACH trial
that patients with PAD have an increased risk of major
cardiovascular events6,7 and a poor control of their cardio-
vascular risk factors.33 The treatment approach for patients
with asymptomatic PAD is modification of atherosclerotic
risk factors, including smoking cessation, control of hyper-
tension and hypercholesterolemia, optimal management of
diabetes and exercise therapy, as well as pharmacologic
therapy for event prevention (antiplatelets and angiotensin
converting enzyme inhibitors).19,23 Thus, identifying pa-
tients with asymptomatic PAD is essential in order to
reduce morbidity and mortality.
For this study to be as useful as possible for physicians
practicing in metropolitan France, the enrollment plan was
designed to sample patients throughout the country. Phy-
sicians were instructed to enroll the first 10 patients who
met study criteria; however, there were no log books au-
dited to ensure compliance with these instructions. Never-
theless, we feel confident that the results presented here can
be extrapolated to most hospitals in France. Another pos-
sible study limitation is that we did not conduct inter- or
intraobserver variability and accuracy testing on the pulse
examinations conducted as part of the initial patient exam-
ination to determine eligibility for entry into the study.
Nevertheless, possible influence of inaccuracy in pulse ex-
amination was minimized because all participating physi-
cians received specific training for taking study measure-
ments, and pulse examination was not the sole criterion for
establishing the presence of symptomatic PAD.CONCLUSIONS
Based on ABI measurements, the prevalence of asymp-
tomatic PAD in patients, at cardiovascular risk, hospitalized
throughout France was 41%. This high prevalence rate
underscores the fact that many patients who are considered
at low risk of having a cardiovascular event may in fact have
asymptomatic PAD and therefore may be at high risk.
Furthermore, we showed that ABI, which is a reliable,
guideline-endorsed technique, was evaluated by physicians
as being useful and easy to perform. Together, these data
suggest that to ensure that appropriate secondary preven-
tion treatments are initiated, the systematic use of ABI to
screen for atherothrombotic localizations is warranted in
hospitalized patients who have established atherothrom-
botic disease or are both at cardiovascular risk and over the
age of 55.
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